The company has not filed an annual or quarterly report since its Q2 FY2023 10-Q, filed Aug 4, 2023. Its latest SEC filing is a CT ORDER from Sep 18, 2023.
10-Q for Q2 FY2023, filed Aug 4, 2023
The sections below describe the company as of the FY2022 annual report.
Develops oral antiviral drug candidates for patients with coronavirus disease and other viral diseases.
10-K for FY2022, filed Mar 14, 2023We are a clinical-stage biopharmaceutical company that is focused on discovering, developing and commercializing novel therapeutics to…View ↗
By leveraging our understanding of structure-based drug design, reversible covalent chemistry and viral biology, we have discovered and are…View ↗
Complete nonclinical and clinical development and seek approval for our lead product candidate, pomotrelvir, an investigational, orally…View ↗
No revenue was reported.
10-K for FY2022, filed Mar 14, 2023
10-Q for Q2 FY2023, filed Aug 4, 2023
−$10.8MView ↗
8-K, filed Aug 31, 2023
On August 31, 2023, as a result of its acceptance of, and payment for, the shares of Common Stock tendered in the Offer, Merger Sub…View ↗
8-K, filed Jul 17, 2023
On July 16, 2023, Pardes Biosciences, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with…View ↗
8-K, filed Apr 3, 2023
CARLSBAD, Calif. April 03, 2023 (GLOBE NEWSWIRE) – Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company…View ↗
Competes with Gilead Sciences, Pfizer, Merck &, Shionogi, Enanta Pharmaceuticals, and Atea Pharmaceuticals
10-K for FY2022, filed Mar 14, 2023The key competitive factors affecting the success of any product candidates that we develop, if approved, are likely to include their…View ↗
Loading...
